In the second quarter of 2017, biopharma companies brought in a total of $13.4 billion in financing, nearly doubling the first quarter's $6.8 billion aggregate. Initial public offerings boasted the highest dollar value, reaching $4.7 billion, or over one-third of the total. Interestingly, this financing type had one of the lowest volume counts – 18 – during the quarter, indicating the average IPO transaction was quite high. (See Exhibit 1.)
Biopharma Quarterly Deal-Making Statistics, Q2 2017
A look at financing, M&A and alliance activity April–June 2017
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.
More from Deal-Making
More from In Vivo
• By
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
• By
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
• By
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.